Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect

Proteasome inhibitors (PIs) represent the gold standard in the treatment of multiple myeloma. Among PIs, Bortezomib (BTZ) is frequently used as first line therapy, but peripheral neuropathy (PN), occurring approximately in 50% of patients, impairs their life, representing a dose-limiting toxicity. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Malacrida, A., Semperboni, S., Di Domizio, A., Palmioli, A., Broggi, L., Airoldi, C., Meregalli, C., Cavaletti, G., Nicolini, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131610/
https://www.ncbi.nlm.nih.gov/pubmed/34006972
http://dx.doi.org/10.1038/s41598-021-89856-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131610/
https://www.ncbi.nlm.nih.gov/pubmed/34006972
http://dx.doi.org/10.1038/s41598-021-89856-3

Ejemplares similares